Decoding TG Therapeutics's Options Activity: What's the Big Picture?
Portfolio Pulse from Benzinga Insights
TG Therapeutics (NASDAQ:TGTX) has seen significant bullish options activity, with 63% of trades being bullish. The stock price is up 13.68% to $25.1, and analysts have mixed ratings with target prices ranging from $20 to $49. The company focuses on treatments for B-cell diseases and has FDA approval for BRIUMVI.
August 19, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics has experienced a bullish trend in options trading, with 63% of trades being bullish. The stock price has increased by 13.68% to $25.1. Analysts have mixed ratings, with target prices ranging from $20 to $49.
The significant bullish options activity suggests positive sentiment among investors, which is reflected in the recent stock price increase. Analysts' target prices indicate potential for further growth, although opinions vary.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100